PDR001 drug page Clinical trials

Trials with PDR001

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

5Trials
0Recruiting
17Countries
984Planned patients

Showing 1–5 of 5

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Ongoing, not recruiting Phase 1 98 patients NCT03891953

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy…

United States, Germany, Hong Kong, Japan and 2 more May 2019 – Oct 2026 Interventional
Combined with: DKY709
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Finished Phase 1 120 patients NCT02947165

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

United States, Austria, Canada, Germany and 5 more Apr 2017 – Jun 2021 Interventional
Combined with: NIS793
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Finished Phase 1 298 patients NCT02890069

The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, ph…

United States, Germany, Netherlands, South Korea and 3 more Oct 2016 – Feb 2022 Interventional
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Finished Phase 1 283 patients NCT02900664

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerabilit…

United States, Belgium, Canada, France and 5 more Aug 2016 – Mar 2021 Interventional
Combined with: ACZ885CJM112EGF816TMT212
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Finished Phase 1 185 patients NCT01351103

The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite standard …

United States, Canada, France, Germany and 3 more Dec 2011 – Jun 2024 Interventional
Combined with: LGK974